Abstract
A case of papaverine-induced elevated liver function tests occurred in a 58-year-old female with peripheral vascular disease after she received papaverine hydrochloride 150 mg bid over a two- to three-week period. The patient presented with abnormal elevations in serum transaminases (SGOT and SGPT) and alkaline phosphatase. The papaverine was discontinued, and the elevated enzymes returned to normal within three weeks.
Get full access to this article
View all access options for this article.
References
1.
Rønnov-Jessen V.
,
Tjerlund A.
Hepatotoxicity due to treatment with papaverine . N Engl J Med 1969 ; 281 : 1333 –5 .
2.
Wade A.
,
Reynolds J.
, eds. Martindale: the extra pharmacopoeia. London : The Pharmaceutical Press , 1977 : 1043 –4 .
3.
Nickerson M.
Vasodilator drugs . In:
Goodman L.
,
Gilman A.
, eds. The pharmacological basis of therapeutics. New York : Macmillan , 1975 : 735 .
4.
Driemen P.
Papaverine — hepatotoxic or not? J Am Geriatr Soc 1973 ; 21 : 202 –5 .
5.
Kiaer H.
,
Olsen S.
,
Rannov-Jessen V.
Hepatotoxicity of papaverine . Arch Pathol 1974 ; 98 : 292 –6 .
6.
Klatskin G.
Toxic and drug-induced hepatitis . In:
Schiff L.
, ed. Diseases of the liver. Philadelphia : JB Lippincott , 1969 : 498 –601 .
7.Product information, papaverine hydrochloride. Columbus, OH : Philips Roxane Laboratories , 1974 .
8.
Zimmerman H.
Papaverine revisited as a hepatotoxin . N Engl J Med 1969 ; 281 : 1364 –5 .
9.
Lien E.
,
Lien L.
Structure side-effect sorting of drugs III: hepatotoxicities . California Pharmacist 1978 ; 26 : 34 –44 .